Incyte
INCY
Market cap $15B

77.55 USD

+0.17

0.22%

At close Jul 30, 4:00 PM EDT

After hours

76.74

-0.81

1.04%

1 day

0.22%

5 days

9.52%

1 month

13.88%

3 months

23.76%

6 months

5.12%

Year to date

11.53%

1 year

14.40%

5 years

-22.84%

10 years

-24.68%

About: Incyte focuses on the discovery and development of small-molecule drugs. The firm's leading drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis and 2022 for vitiligo. Incyte's pipeline includes a broad array of oncology and dermatology programs.

Employees: 2,617

Healthcare Biotechnology

0

Funds holding %

of 7,323 funds

0

Analysts bullish %

of 9 analysts

Fund manager confidence

Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)

57% more call options, than puts

Call options by funds: $47.5M | Put options by funds: $30.3M

16% more repeat investments, than reductions

Existing positions increased: 252 | Existing positions reduced: 217

2.83% more ownership

Funds ownership: 94.68% [Q4 2024] → 97.51% (+2.83%) [Q1 2025]

10% less first-time investments, than exits

New positions opened: 74 | Existing positions closed: 82

3% less funds holding

Funds holding: 637 [Q4 2024] → 615 (-22) [Q1 2025]

9% less capital invested

Capital invested by funds: $12.6B [Q4 2024] → $11.4B (-$1.18B) [Q1 2025]

50% less funds holding in top 10

Funds holding in top 10: 8 [Q4 2024] → 4 (-4) [Q1 2025]

See Fund Rankings

Research analyst outlook

9 Wall Street Analysts provided 1 year price targets over the past 3 months

Low target

$60

23%

downside

Avg. target

$76

2%

downside

High target

$107

38%

upside

9 analyst ratings

2 positive

22%

6 neutral

67%

1 negative

11%

BMO Capital Evan Seigerman	23%downside $60	Underperform Maintained	30 Jul 2025
Citigroup David Lebowitz	33%upside $103	Buy Maintained	30 Jul 2025
Truist Securities Srikripa Devarakonda	2%upside $79	Hold Maintained	30 Jul 2025
UBS Nicholas Holowko	12%downside $68	Neutral Maintained	30 Jul 2025
RBC Capital Brian Abrahams	7%downside $72	Sector Perform Maintained	30 Jul 2025

See Analyst Rankings

Financial journalist opinion

Based on 18 articles about INCY published over the past 30 days

Zacks Investment Research

Why Incyte (INCY) is a Top Value Stock for the Long-Term

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

Why Incyte (INCY) is a Top Value Stock for the Long-Term

Incyte Corporation (INCY) Q2 2025 Earnings Call Transcript

Incyte Corporation (NASDAQ:INCY ) Q2 2025 Earnings Conference Call July 29, 2025 8:00 AM ET Company Participants Christiana Stamoulis - Executive VP & CFO Greg Shertzer - Senior Director of Investor Relations Mohamed Issa - Executive Vice President & Head of U.S. Oncology Pablo J. Cagnoni - President and Head of Research & Development William Meury - CEO, President & Director Conference Call Participants Brian Corey Abrahams - RBC Capital Markets, Research Division Conor Thomas MacKay - BMO Capital Markets Equity Research David Neil Lebowitz - Citigroup Inc., Research Division Gavin Clark-Gartner - Evercore ISI Institutional Equities, Research Division Jay Olson - Oppenheimer & Co. Inc., Research Division Jessica Macomber Fye - JPMorgan Chase & Co, Research Division Marc Alan Frahm - TD Cowen, Research Division Michael Werner Schmidt - Guggenheim Securities, LLC, Research Division Salim Qader Syed - Mizuho Securities USA LLC, Research Division Salveen Jaswal Richter - Goldman Sachs Group, Inc., Research Division Srikripa Devarakonda - Truist Securities, Inc., Research Division Stephen Douglas Willey - Stifel, Nicolaus & Company, Incorporated, Research Division Tazeen Ahmad - BofA Securities, Research Division Yuxi Dong - Jefferies LLC, Research Division Operator Greetings, and welcome to the Incyte Second Quarter 2025 Earnings Conference Call and Webcast.

Incyte Corporation (INCY) Q2 2025 Earnings Call Transcript

Zacks Investment Research

INCY's Q2 Earnings & Revenues Beat Estimates on Higher Product Sales

Incyte reports better-than-expected second-quarter 2025 results, beating both earnings and revenue estimates, driven by strong Jakafi and Opzelura sales.

INCY's Q2 Earnings & Revenues Beat Estimates on Higher Product Sales

Incyte Surges Past Expectations With Strong Q2, Boosts Guidance On Jakafi Demand

Incyte Corporation INCY reported on Tuesday that its second-quarter revenue was $1.22 billion, up 16% year over year. The company beat the consensus of $1.15 billion.

Incyte Surges Past Expectations With Strong Q2, Boosts Guidance On Jakafi Demand

Zacks Investment Research

Incyte (INCY) Reports Q2 Earnings: What Key Metrics Have to Say

While the top- and bottom-line numbers for Incyte (INCY) give a sense of how the business performed in the quarter ended June 2025, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.

Incyte (INCY) Reports Q2 Earnings: What Key Metrics Have to Say

Zacks Investment Research

Incyte (INCY) Surpasses Q2 Earnings and Revenue Estimates

Incyte (INCY) came out with quarterly earnings of $1.57 per share, beating the Zacks Consensus Estimate of $1.39 per share. This compares to a loss of $1.82 per share a year ago.

Incyte (INCY) Surpasses Q2 Earnings and Revenue Estimates

Incyte lifts annual sales forecast for blood cancer drug after solid quarter

Incyte Corp on Tuesday raised its annual sales forecast for blood cancer treatment Jakafi after robust demand helped the company surpass Wall Street estimates for second-quarter revenue and profit.

Incyte lifts annual sales forecast for blood cancer drug after solid quarter

Incyte Reports 2025 Second Quarter Financial Results and Provides Updates on Key Clinical Programs

WILMINGTON, Del.--(BUSINESS WIRE)---- $INCY--Incyte Reports 2025 Second Quarter Financial Results and Provides Updates on Key Clinical Programs.

Incyte Reports 2025 Second Quarter Financial Results and Provides Updates on Key Clinical Programs

Zacks Investment Research

Why Investors Need to Take Advantage of These 2 Medical Stocks Now

Why investors should use the Zacks Earnings ESP tool to help find stocks that are poised to top quarterly earnings estimates.

Why Investors Need to Take Advantage of These 2 Medical Stocks Now

Incyte To Present Initial Data for its TGFβR2×PD-1-directed Bispecific Antibody (INCA33890) and its Selective Inhibitor of G12D-mutated KRAS (INCB161734) at the European Society of Medical Oncology (ESMO) Congress 2025

WILMINGTON, Del.--(BUSINESS WIRE)---- $INCY--Data for Incyte's TGFβR2×PD-1-directed Bispecific Antibody (INCA33890) and Selective Inhibitor of G12D-mutated KRAS (INCB161734) Accepted at ESMO 2025.

Incyte To Present Initial Data for its TGFβR2×PD-1-directed Bispecific Antibody (INCA33890) and its Selective Inhibitor of G12D-mutated KRAS (INCB161734) at the European Society of Medical Oncology (ESMO) Congress 2025

See News Rankings

Charts implemented using Lightweight Charts™